Your AI-Trained Oncology Knowledge Connection!
Research presented at the 2021 San Antonio Breast Cancer Symposium highlighted survival improvements for postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer when treated with ribociclib plus letrozole over placebo.
Those with higher Oncotype DX scores may be more likely to complete the recommended 5 years of endocrine therapy for breast cancer.
Pooled efficacy and safety data confirm that patients who self-identify as Black or Hispanic can be safely treated with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.
Patients with early triple-negative breast cancer across prespecified subgroups who were given neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab in a phase 3 trial saw an improvement in event-free survival.
Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.
Results of a phase 3 trial presented at 2021 SABCS indicated that entinostat plus exemestane improved progression-free survival for Chinese patients with advanced hormone receptor–positive breast cancer vs placebo.
Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.
The latest podcast episode of Oncology Peer Review On-The-Go features a conversation with Tzvia Bader and Karine Perreault on TrialJectory’s platform, which seeks to guide patients with cancer on their treatment journey.
Patients with hormone receptor-positive, HER2-negative early breast cancer did not see a benefit when adjuvant palbociclib was added to standard endocrine therapy.
Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.
A phase 3 trial analysis found that metformin does not improve invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status.
Fulvestrant plus palbociclib after aromatase inhibitor plus palbociclib led to improvements in progression-free survival for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Elacestrant significantly improved progression-free survival in estrogen receptor–positive HER2-negative metastatic breast cancer.
A pooled analysis found that genomic alterations identified through multigene sequencing led to progression-free survival improvements over maintenance chemotherapy for HER2-negative metastatic breast cancer.
Black women with breast cancer had a 3.5-fold higher rate of lymphedema over 24 months compared with White women.
Treatment with tamoxifen for primary breast cancer may result in increased risk of developing subsequent uterine cancer by activating the PI3K pathway.
Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.
Patients with newly diagnosed glioblastoma who were treated with paxalisib saw positive efficacy and safety results.
Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.
A United States indication for duvelisib in previously treated relapsed/refractory follicular lymphoma has been voluntarily withdrawn by developer Secura Bio following an assessment of the drug and subsequent consultation with the FDA.
Susan M. O'Brien, MD, discusses breakthroughs in the treatment of chronic lymphocytic leukemia throughout the preceding year.
The use of alectinib to treat ALK-positive non–small cell lung cancer resulted in better overall survival compared with ceritinib.
The phase 3 ARASENS trial, which assessed the use of darolutamide and docetaxel in patients with metastatic hormone-sensitive prostate cancer, met its primary end point of significantly improved overall survival.
Compared with whole brain radiotherapy alone, the addition of local radiation boost to whole brain radiotherapy improved overall survival and progression-free survival among patients with small cell lung cancer and brain metastases.
The phase 2 MK-6482-004 trial found that belzutifan produced positive response data for patients with renal cell carcinoma and non–renal cell carcinoma neoplasms associated with von Hippel-Lindau disease.
Researchers utilized the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to examine the prognostic impact on survival of pre-treatment health-related quality of life parameters for patients with newly diagnosed mantle cell lymphoma.
Samilia Obeng-Gyasi discussed the connection between stress and allostatic load and chemotherapy completion in patients with breast cancer.
A study from the Yale Cancer Center potentially introduces a drug design platform to fight drug resistance for patients with HER2-positive breast cancer and ovarian cancer.
The National Comprehensive Cancer Network has reversed its previous ruling in September and instead recommends patients with low-risk prostate cancer receive active surveillance.
The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.
